Gastroesophageal cancer

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This trial tests an experimental drug called zanidatamab, which targets HER2, a protein that fuels certain breast and stomach cancers. Researchers give zanidatamab alongside chemotherapy, and sometimes with the immunotherapy tislelizumab, to people with advanced HER2-positive bre…

This phase 2 trial tests whether combining two drugs—cabozantinib and pembrolizumab—can slow or stop the growth of advanced gastric or gastroesophageal cancer. The study enrolls people whose cancer has worsened despite at least one prior chemotherapy treatment. Researchers will m…

This study tests whether a combination of ramucirumab plus FOLFIRI (a standard chemo regimen) works better than ramucirumab plus paclitaxel for people with advanced stomach or gastroesophageal junction cancer that has worsened after one prior chemo treatment. About 429 participan…

This phase 3 trial tested whether a combination of two drugs, regorafenib and nivolumab, helps people with advanced gastro-oesophageal cancer live longer than standard chemotherapy. The study included 462 adults whose cancer had stopped responding to prior treatments. The goal wa…

This study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find safe doses and see if the drug could shrink tumors. The study is complete, but results are not yet available…

This phase 2 trial tested a combination of radiation, a targeted drug (olaparib), and an immunotherapy (pembrolizumab) in 9 people with advanced stomach or gastroesophageal junction cancer that had spread. The goal was to see if this approach could shrink tumors that were not dir…

This study tested a new drug called gentuximab combined with the chemotherapy drug paclitaxel in 76 people with advanced stomach or gastroesophageal junction cancer that had worsened after initial treatment. The goal was to find a safe and effective dose and see if the combinatio…

This pilot study tested a combination of chemotherapy drugs (FOLFIRINOX plus paclitaxel and carboplatin) along with proton beam radiation before surgery in 25 people with gastroesophageal cancer. The goal was to see if this intense pre-surgery treatment could shrink tumors and be…

This early-phase study tested a new drug called gevokizumab alongside standard cancer treatments in 167 adults with advanced colorectal, stomach, or kidney cancer that had spread. The goal was to find a safe and active dose and see if the combination could help control the diseas…

This study compared two chemotherapy regimens (FOLFOX and CarboP-pacliT) given with radiation before surgery for esophageal or junction cancer. 106 patients were enrolled to see which treatment leads to better tumor removal and fewer serious complications. The goal is to help doc…

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before and after surgery helps people with stomach or gastroesophageal junction cancer. Over 1,000 participants received either pembrolizumab plus chemo or placebo pl…

This study tested whether adding the drug pembrolizumab to standard chemotherapy helps Chinese adults with stomach or gastroesophageal junction cancer. Participants received the drug combination or a placebo before and after surgery. The goal was to see if the combination improve…

This study tested whether adding radiation to chemotherapy before surgery improves outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 204 adults with operable tumors received either chemotherapy alone or chemotherapy plus radiation before…

This Phase 3 trial tested whether adding the immunotherapy drug camrelizumab to standard chemotherapy, followed by camrelizumab plus the targeted drug apatinib, helps people with advanced stomach or gastroesophageal junction cancer live longer. The study enrolled 885 participants…

This study tested a new type of PET scan (FAPI) in 20 people with stomach or gastro-esophageal junction cancer. The goal was to see if FAPI scans are more accurate than standard scans for determining the cancer stage before and after chemotherapy. By comparing scan results with t…

This study tests whether a CT-guided nerve block called celiac plexus neurolysis can relieve severe abdominal pain in people with upper gastrointestinal cancer better than standard pain medication. About 110 adults with biopsy-proven upper GI cancer and severe pain will be random…

This study tests a program that provides remote nutrition counseling and uses a Fitbit to track activity and diet for people with gastroesophageal cancer. Participants log their food intake and meet with a dietitian via video calls. The goal is to see if this approach is practica…

This phase II trial tested a concentrated plant dietary supplement (made from foods like taro, rice, and carrots) in 30 people with gastrointestinal cancers who had diarrhea from chemotherapy. Participants received the supplement alongside standard anti-diarrheal treatment. The g…

This study tested whether teaching emotional skills (like identifying and managing feelings) can help people who finished cancer treatment. 26 patients with digestive or lung cancer took part. Some received emotional skills training, others did relaxation exercises. The goal was …

This study followed 159 people with metastatic colorectal, pancreatic, biliary, or esophageal cancers who were starting a new line of therapy. Researchers collected blood samples (tumor markers and liquid biopsies) and patient-reported quality-of-life data to see if these could p…

This completed study collected surgical drain fluid and blood from 10 patients who had surgery for stomach or esophageal cancer. Researchers analyzed these samples for molecular markers that might predict how well a patient would respond to immunotherapy. The goal was to establis…

This study followed 196 people with advanced lung or stomach cancer who had not yet received treatment. Researchers wanted to see if emotional distress before starting immunotherapy, along with certain blood markers of inflammation and metabolism, could predict how long patients …

This study looked back at medical records of 260 adults in China with advanced stomach or gastroesophageal junction cancer who received nivolumab as their first treatment. The goal was to see how well the drug worked in everyday practice and what treatment patterns were used. No …